BridgeBio Pharma, Inc. (BBIO) Cash Flow Statement
BridgeBio Pharma, Inc. (BBIO) generated -$434.4M of operating cash flow over the twelve months to 2026-06-30, spent $1.0M on capital expenditure and had free cash flow of -$435.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BBIOBridgeBio Pharma, Inc.Follow BBIO — free
—
Price chart with a free account
- Market cap
- 13.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.25 | -0.40 | -0.50 | -0.42 | -0.53 | -0.52 | -0.45 | -0.43 | |
| Capital expenditure | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | -0.26 | -0.41 | -0.51 | -0.42 | -0.53 | -0.52 | -0.45 | -0.44 | |
| Dividends paid | 0.00 | — | — | — | — | — | — | — | |
| Share repurchases | — | 0.08 | 0.20 | 0.00 | 0.00 | 0.00 | 0.05 | — | |
| Stock-based compensation | 0.02 | 0.06 | 0.10 | 0.09 | 0.11 | 0.10 | 0.13 | — |
USD billions · SEC XBRL
BridgeBio Pharma, Inc. — questions
- What is BridgeBio Pharma, Inc.'s operating cash flow?
- -$434.4M over the twelve months to 2026-06-30.
- How much does BridgeBio Pharma, Inc. spend on capital expenditure?
- $1.0M over the twelve months to 2026-06-30.
- What is BridgeBio Pharma, Inc.'s free cash flow?
- -$435.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from BridgeBio Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.